Acquiring Company
NEXGEL
Acquired Company
BioNX
Langhorne
CanadaBiotechnologyHealth CareDescription
Nexgel has successfully closed the acquisition of BioNX in mid-April, adding a portfolio of six regenerative biomaterial products to its offerings. The acquisition is expected to triple Nexgel's annual revenue to approximately $35 million and is projected to be immediately accretive to profitability. Although no contribution from BioNX was recorded in the quarter's financials, management anticipates partial revenue recognition from BioNX in the next quarter. This acquisition aligns with Nexgel's strategy for growth in the regenerative medicine market.
Other recent acquisitions in Biotechnology and Health Care
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Cencora integrates COR clinical services acquisition (June 29, 2026)
- Alkem Medtech to acquire majority stake in Occlutech (June 29, 2026)
- AMR Clinical acquires ClinOhio Research Services (June 29, 2026)
- Flerie merges with Biosergen in strategic acquisition (June 26, 2026)
- GenCurix to merge with Genopix for cancer diagnostics (June 26, 2026)
- Merck KGaA to acquire Bio-Techne Corporation (June 25, 2026)
Who to call at NEXGEL, and when
When NEXGEL changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day NEXGEL raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at NEXGEL, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at NEXGEL. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment NEXGEL makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired BioNX?
BioNX was acquired by NEXGEL, based in Langhorne. The deal was reported on May 15, 2026. Nexgel is a company focused on developing and commercializing innovative hydrogel products. They specialize in regenerative biomaterials and have a range of products in various stages of development. NEXGEL is publicly traded (NXGL) and operates in Biotechnology.
When did NEXGEL acquire BioNX?
NEXGEL's acquisition of BioNX was reported on May 15, 2026. Nexgel has successfully closed the acquisition of BioNX in mid-April, adding a portfolio of six regenerative biomaterial products to its offerings. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does BioNX do?
BioNX is known for its commercial-stage regenerative biomaterial products. The company has a portfolio that includes products with over a decade of clinical use. Their technologies have been implemented in approximately 500 U.S. It is privately held, and is based in Canada.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.